Ex parte BARNETT et al. - Page 4



            Appeal No. 1996-1090                                                 
            Application No, 08/027,974                                           



            with a CEA family member involves routine techniques."4              
            This is supported by a declaration (paper no. 18, p. 5)              
            which states that "confirming a given fragment exhibits              
            immunological cross-reactivity with a CEA family member              
            also does not present any undue obstacle and is within               
            the skill of the ordinary practitioner in the art."                  
            Examiner does not appear to challenge these statements               
            and in fact concedes that antibodies can be made from the            
            claimed fragment,5 a necessary step to achieving a cross-            
            reactivity with a CEA family member.  If antibodies can              
            be made from the claimed fragment and no undue                       
            experimentation is required to react the antibodies with             
            CEA molecules, it follows therefore that the                         
            specification fully enables one to use the claimed                   
            fragment I in obtaining antibodies for reactivity with               
            CEA molecules.                                                       
                Examiner takes the position6 that while one might be             
                                                                                 
            4 "The examiner concedes that obtaining the fragments is             
            not a basis for this rejection.  The Examiner also                   
            apparently concedes that the determination of which                  
            fragments exhibit cross-reactivity with a CEA family                 
            member involves routine techniques."  Brief, p. 12.                  
                                                                                
            5 "Appellants' distortion of the enablement rejection                
            does not make since [sense, sic] as Examiner has                     
            repeatedly conceded that one can make peptides and raise             
            antibodies to them."  Examiner's Answer, p. 4.                       
                                                                                
            6 "Appellant's arguments are deceptive in that [they,                
            sic] argue against rejections that are not of record.  In            
            paper 14 [Advisory Action] page 3, lines 5-7 the Examiner            
                        4                                                        



Page:  Previous  1  2  3  4  5  6  7  8  9  Next 

Last modified: November 3, 2007